You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?
Hexagon Q3’24: Soft performance & potential spin-offs
Hexagon’s cyclical headwinds continued in Q3, but the improved revenue mix contributed to gross margin growth. A plan to potentially spin off certain fast-growing, highly profitable, software-focused parts of the group was announced. Analyst Pauli Lohi summarizes.
00:00 Intro
00:10 Cyclical headwinds
02:01 Revenue mix
02:27 Spin-off plans
04:35 Valuation & recommendation
Read the latest research, published 10/28/2024:
Hexagon Q3'24: Spin-off could simplify company structure
See the latest analyst interview, published 8/6/2024:
Hexagon Q2’24: Recurring revenue grows
Herantis Pharma as an Investment | Life Science Night Dec. 2, 2024
Aiforia as an Investment | Life Science Night Dec. 2, 2024
Faron Pharmaceuticals as an Investment | Life Science Night Dec. 2, 2024
Life Science Companies as Investments | Life Science Night Dec. 2, 2024
Life Science Night | December 2, 2024
View all videos